TRIANA Biomedicines

Focus: TRIANA Biomedicines is a public biotech company focused on discovering and developing molecular glues targeting E3 ubiquitin ligases, a cutting-edge protein degradation platform. Based in Lexington, MA, the company operates at an early clinical stage with minimal public disclosure of scale.

Unknown

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About TRIANA Biomedicines

AI assessmentNot Hiring

No open roles listed right now. Follow TRIANA Biomedicines to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

1 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

TRI-611

ALK-positive NSCLC

PHASE_1_2

Clinical Trials (1)

NCT07491497A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC

Phase 1/2

Help build intelligence for TRIANA Biomedicines

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Platform-driven discovery model targeting E3 ligases offers exposure to high-impact, mechanistically novel therapeutic approach with significant IP moat potential
Public company status provides equity upside potential and operational transparency absent in private biotech
Early-stage pipeline (Phase 1/2) means opportunity to shape drug development strategy and clinical program design from ground level

Watch Out For

Only 1 active clinical trial reported (TRI-611) suggests limited pipeline depth and compressed near-term catalysts for value creation
Minimal hiring activity (1 open role) and absent employee count data indicate either very early scaling phase or constrained growth trajectory
Zero published scientific output and sparse public information suggest limited visibility into platform validation and competitive differentiation

Generated by Claude from TRIANA Biomedicines's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 1 clinical trial

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

1 pipeline

Marketed

Pipeline